Structural basis of selective TRPM7 inhibition by the anticancer agent CCT128930

Nadezhdin, Kirill D.; Correia, Leonor; Shalygin, Alexey; Aktolun, Muhammed; Neuberger, Arthur; Gudermann, Thomas; Kurnikova, Maria G.; Chubanov, Vladimir; Sobolevsky, Alexander I.

doi:10.1016/j.celrep.2024.114108

Cell Reports

2024

DOI: 10.1016/j.celrep.2024.114108

|View full text |Cite

Structural basis of selective TRPM7 inhibition by the anticancer agent CCT128930

Kirill D. Nadezhdin,

Leonor Correia,

Alexey Shalygin

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Structure-function analyses of human TRPV6 ancestral and derived haplotypes

Neuberger,

Shalygin,

Trofimov

et al. 2024

Structure

View full text Add to dashboard Cite

Structure-function analyses of human TRPV6 ancestral and derived haplotypes

Neuberger,

Shalygin,

Trofimov

et al. 2024

Structure

View full text Add to dashboard Cite

Expression Profiling Identified TRPM7 and HER2 as Potential Targets for the Combined Treatment of Cancer Cells

Egawa,

Schmücker,

Grimm

et al. 2024

Cells

View full text Add to dashboard Cite

TRPM7 is a divalent cation-permeable channel that is highly active in cancer cells. The pharmacological inhibitors of TRPM7 have been shown to suppress the proliferation of tumor cells, highlighting TRPM7 as a new anticancer drug target. However, the potential benefit of combining TRPM7 inhibitors with conventional anticancer therapies remains unexplored. Here, we used genome-wide transcriptome profiling of human leukemia HAP1 cells to examine cellular responses caused by the application of NS8593, the potent inhibitor of the TRPM7 channel, in comparison with two independent knockout mutations in the TRPM7 gene introduced by the CRISPR/Cas9 approach. This analysis revealed that TRPM7 regulates the expression levels of several transcripts, including HER2 (ERBB2). Consequently, we examined the TRPM7/HER2 axis in several non-hematopoietic cells to show that TRPM7 affects the expression of HER2 protein in a Zn2+-dependent fashion. Moreover, we found that co-administration of pharmacological inhibitors of HER2 and TRPM7 elicited a synergistic antiproliferative effect on HER2-overexpressing SKBR3 cells but not on HER2-deficient MDA-MB-231 breast cancer cells. Hence, our study proposes a new combinatorial strategy for treating HER2-positive breast cancer cells.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Structural basis of selective TRPM7 inhibition by the anticancer agent CCT128930

Cited by 2 publications

References 59 publications

Structure-function analyses of human TRPV6 ancestral and derived haplotypes

Structure-function analyses of human TRPV6 ancestral and derived haplotypes

Expression Profiling Identified TRPM7 and HER2 as Potential Targets for the Combined Treatment of Cancer Cells

Contact Info

Product

Resources

About